Vemurafenib induces senescence features in melanoma cells.


A large proportion of human melanomas harbor a mutation leading to permanent activation of the serine/threonine kinase BRAF, and as a consequence, they have developed dependence on BRAF/mitogen-activated protein kinase signaling. Accordingly, BRAF inhibitors such as Vemurafenib show a good anti-tumorigenic effect on metastases with the BRAF(V600E) mutation… (More)
DOI: 10.1038/jid.2013.6

6 Figures and Tables


  • Presentations referencing similar topics